OGN Valuation

Organon & Co

Add to Watchlist

Advanced Chart

10.570

+0.12(1.148%)1D

Overview
Forecast
Valuation
Earnings

OGN Relative Valuation

OGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, OGN is overvalued; if below, it's undervalued.

Historical Valuation

Organon & Co (OGN) is now in the Undervalued zone, suggesting that its current forward PE ratio of 2.82 is considered Undervalued compared with the five-year average of 4.94. The fair price of Organon & Co (OGN) is between 24.88 to 33.05 according to relative valuation methord. Compared to the current price of 10.57 USD , Organon & Co is Undervalued By 57.51%.

Relative Value

Fair Zone

24.88-33.05

Current Price：10.57

57.51%

Undervalued

2.82

Trailing

Forward

5.56

EV/EBITDA

Organon & Co. (OGN) has a current EV/EBITDA of 5.56. The 5-year average EV/EBITDA is 6.67. The thresholds are as follows: Strongly Undervalued below 4.44, Undervalued between 4.44 and 5.56, Fairly Valued between 7.79 and 5.56, Overvalued between 7.79 and 8.90, and Strongly Overvalued above 8.90. The current Forward EV/EBITDA of 5.56 falls within the Historic Trend Line -Fairly Valued range.

6.27

EV/EBIT

Organon & Co. (OGN) has a current EV/EBIT of 6.27. The 5-year average EV/EBIT is 7.19. The thresholds are as follows: Strongly Undervalued below 4.78, Undervalued between 4.78 and 5.98, Fairly Valued between 8.40 and 5.98, Overvalued between 8.40 and 9.60, and Strongly Overvalued above 9.60. The current Forward EV/EBIT of 6.27 falls within the Historic Trend Line -Fairly Valued range.

0.43

Organon & Co. (OGN) has a current PS of 0.43. The 5-year average PS is 0.93. The thresholds are as follows: Strongly Undervalued below 0.26, Undervalued between 0.26 and 0.60, Fairly Valued between 1.27 and 0.60, Overvalued between 1.27 and 1.60, and Strongly Overvalued above 1.60. The current Forward PS of 0.43 falls within the Undervalued range.

2.93

P/OCF

Organon & Co. (OGN) has a current P/OCF of 2.93. The 5-year average P/OCF is 4.92. The thresholds are as follows: Strongly Undervalued below 1.73, Undervalued between 1.73 and 3.33, Fairly Valued between 6.51 and 3.33, Overvalued between 6.51 and 8.10, and Strongly Overvalued above 8.10. The current Forward P/OCF of 2.93 falls within the Undervalued range.

3.14

P/FCF

Organon & Co. (OGN) has a current P/FCF of 3.14. The 5-year average P/FCF is 5.88. The thresholds are as follows: Strongly Undervalued below 0.39, Undervalued between 0.39 and 3.14, Fairly Valued between 8.63 and 3.14, Overvalued between 8.63 and 11.38, and Strongly Overvalued above 11.38. The current Forward P/FCF of 3.14 falls within the Historic Trend Line -Fairly Valued range.

Organon & Co (OGN) has a current Price-to-Book (P/B) ratio of 3.75. Compared to its 3-year average P/B ratio of 6.45 , the current P/B ratio is approximately -41.88% higher. Relative to its 5-year average P/B ratio of 2.81, the current P/B ratio is about 33.46% higher. Organon & Co (OGN) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 14.57%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 17.07% , the current FCF yield is about -100.00% lower.

3.75

P/B

Median3y

6.45

Median5y

2.81

24.22

FCF Yield

Median3y

14.57

Median5y

17.07

Competitors Valuation Multiple

The average P/S ratio for OGN's competitors is 0.00, providing a benchmark for relative valuation. Organon & Co Corp (OGN) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -0.81%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Ultragenyx Pharmaceutical Inc

Kiniksa Pharmaceuticals International PLC

Xenon Pharmaceuticals Inc

Loss

2.88B

SUPN.O

Supernus Pharmaceuticals Inc

Loss

-1.71%

2.63B

Performance Decomposition

Market capitalization of OGN decreased by 42.73% over the past 1 year. The primary factor behind the change was an decrease in Revenue Growth from 1.61B to 1.59B.

The secondary factor is the P/E Change, contributed -16.94%to the performance.

Overall, the performance of OGN in the past 1 year is driven by Revenue Growth. Which is more sustainable.

-0.81%

1.61B → 1.59B

Revenue Growth

-24.98%

12.13 → 9.10

Margin Expansion

-16.94%

4.73 → 3.93

P/E Change

-42.73%